GlassScriptPhysician profile
Clarence H Thomas
NPI 1356326763
$2,080.35
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $358 · 2021: $490.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $289.61 | 2019-2021 | |
| Amgen INC. | $247.71 | 2019-2021 | |
| Lilly USA, LLC | $229.06 | 2019-2021 | |
| Novo Nordisk INC | $210.52 | 2019-2021 | |
| Abbvie INC. | $208.07 | 2021 | |
| Glaxosmithkline, LLC. | $193.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $182.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $116.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.07 | 2019-2021 | |
| Allergan, INC. | $59.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $43.70 | 2021 | |
| Mylan Specialty L.P. | $43.53 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $37.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.63 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.34 | 2020 | |
| Astellas Pharma US INC | $17.79 | 2019 | |
| Abbott Laboratories | $15.99 | 2021 | |
| Amarin Pharma, INC. | $11.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.